Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. by Satoh, M et al.
Autoantibodies to RNA Polymerase 11 Are Common in Systemic Lupus
Erythematosus and Overlap Syndrome
Specific Recognition of the Phosphorylated (110) Form by a Subset of Human Sera
Minoru Satoh, Ajay K. Ajmani, Takashi Ogasawara,* Jenifer J. Langdon, Michito Hirakata,t Jingsong Wang,
and Westley H. Reeves
Departments of Medicine and Microbiology/lmmunology, Thurston Arthritis Research Center and UNC Lineberger Comprehensive
Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599-7280; * Division of Rheumatology and Immunology,
Department of Internal Medicine, University of Missouri, Columbia, Missouri 65212; and * Department of Medicine, Keio University
School of Medicine, Tokyo, 160, Japan
Abstract
Autoantibodies to RNA polymerases (RNAP) I, II, and III
are reported to be highly specific for the diagnosis of sclero-
derma (systemic sclerosis, SSc). In the present study, the
specificity of autoantibodies to RNAP I and III for SSc was
confirmed by immunoprecipitation of 35S-labeled proteins.
However, we report here the previously unrecognized pro-
duction of anti-RNAP H autoantibodies by 9-14% of pa-
tients with SLE and mixed connective tissue disease/overlap
syndrome. 12 out of 32 anti-RNAP H positive sera (group
1) immunoprecipitated a diffuse 220-240-kD band identi-
fied as the largest subunit ofRNAP H whereas the remaining
20 (group 2) immunoprecipitated preferentially the 240-kD
phosphorylated (Ho) form of the large subunit. After pulse
labeling, group 1 sera immunoprecipitated only the 220-kD
(Ila) RNAP H subunit, whereas the diffuse Ha/Ho band
plus the 145-kD second largest RNAP II subunit (Hc) were
immunoprecipitated after several hours of cold chase, sug-
gesting that these sera recognized primarily the largest sub-
unit of RNAP H. Group 2 sera recognized the Ilc subunit
after pulse labeling, and immunoprecipitated the Ilc and
Ho, but not the Ha, subunits after cold chase. Although it
has been suggested that autoantibodies to RNAP II are usu-
ally accompanied by anti-RNAP I/III in SSc, all but one of
the anti-RNAP H positive sera from SLE or mixed connec-
tive tissue disease/overlap syndrome patients, as well as most
of the SSc sera, were negative for anti-RNAP h/IH. More-
over, in contrast to previous reports suggesting that anti-
RNAP antibodies rarely coexist with other SSc subset
marker antibodies, anti-RNAP H antibodies were often ac-
companied by anti-Ku, anti-nRNP, or anti-topoisomerase I
autoantibodies in the present study. We conclude that auto-
antibodies to RNAP H are not a specific marker for SSc,
whereas autoantibodies to RNAP I/III are associated pri-
marily with SSc. In addition, we have identified two distinc-
tive patterns of RNAP H antigen recognition by autoanti-
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bodies, one of them characterized by specific recognition of
the transcriptionally active (phosphorylated) form ofRNAP
H. The clinical significance of these different patterns re-
mains to be determined. (J. Clin. Invest. 1994. 94:1981-
1989.) Key words: RNA polymerase H * autoantibodies .
systemic lupus erythematosus - scleroderma * overlap syn-
drome
Introduction
Certain autoantibodies are highly characteristic of specific dis-
eases, including anti-Sm in SLE (1), anti-topoisomerase I in
scleroderma (systemic sclerosis [SSc]') (2), and anti-amino-
acyl-tRNA synthetases in polymyositis/dermatomyositis (PM/
DM) (3, 4). Other autoantibodies are more closely associated
with particular symptoms regardless of the diagnosis, such as
anti-Ro/SSA and -La/SSB with sicca syndrome (5-7), and anti-
centromere and anti-nRNP antibodies with Raynaud's phenom-
enon (8-10). These autoantibodies may be useful diagnostically
as well as prognostically. Accurately defining the clinical char-
acteristics of patients with a new autoantibody specificity is the
first step to establishing its clinical significance. Recent studies
have stressed the specificity of autoantibodies to RNA polymer-
ases (RNAP) I, H, and III for the diagnosis of SSc (11-15). In
the present studies, we confirmed the diagnostic specificity of
autoantibodies to RNAP I/I1. However, we now report a pre-
viously unrecognized association of autoantibodies to RNAP II
with SLE and SLE-overlap syndrome. In this study, anti-RNAP
II autoantibodies were detected in 9-14% of patients with SLE
and mixed connective tissue disease (MCTD)/overlap syndrome
as well as 20% of patients with SSc without overlapping fea-
tures.
Methods
Diagnostic criteria. The clinical diagnoses of SLE, SSc, and RA were
made based on the ACR criteria (16-18). Sjogren's syndrome was
diagnosed using the criteria of the Ministry of Health and Welfare,
Japanese government, and PM/DM were diagnosed by Bohan's criteria
1. Abbreviations used in this paper: CTD, carboxyl-terminal domain;
MCTD, mixed connective tissue disease; PM/DM polymyositis/derma-
tomyositis; RNAP, RNA polymerase; IIA, nonphosphorylated form of
RNA polymerase II; IIO, phosphorylated form of RNA polymerase LI;
Ila, nonphosphorylated form (220 kD) of RNA polymerase II largest
subunit; Ilo, phosphorylated form (240 kD) of RNA polymerase II
largest subunit; 1Ic, second largest subunit (145 kD) of RNA polymer-
ase II.
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(19, 20). Patients with two or more features each of SLE, SSc, and
PM/DM were classified as MCTD/overlap syndrome. In analyzing the
clinical characteristics of SLE patients with anti-RNAP II autoantibod-
ies, patients meeting four or more SLE criteria along with overlapping
features of SSc or PM/DM were categorized as SLE overlap syndrome.
Human sera and monoclonal antibodies (mAbs). Sera were obtained
from patients with SLE, other autoimmune disorders, pulmonary tuber-
culosis, or cervical carcinoma followed at Keio University Hospital,
National Murayama Hospital, or Fussa Hospital (Tokyo, Japan), or at
the University of North Carolina Hospitals (Chapel Hill, NC). Additional
serum samples were obtained from patients fulfilling ACR criteria for
SLE seen at the Rockefeller University Hospital (New York, NY). Auto-
antibodies to nRNP, Sm, Ro/SS-A, La/SS-B, Jo-l, topoisomerase I, Ku,
and Ki (SL) were determined by double immunodiffusion as described
previously using appropriate reference sera (21). Specificities were also
confirmed by 35S-immunoprecipitation, with the exception of anti-La/
SS-B and anti-Ki. Anti-Su was defined by immunoprecipitation of the
characteristic 100/102-kD doublet and 200-kD polypeptides (Satoh, M.,
J. J. Langdon, C. H. Chou, D. McCauliffe, E. Treadwell, T. Ogasawara,
M. Hirakata, A. Suwa, P. L. Cohen, R. A. Eisenberg, and W. H. Reeves.
Clin. Immunol. Immunopathol. In press).
Reference human autoimmune serum specific for anti-RNAP I/I1
(12, 15), was provided by Dr. Yutaka Okano (University of Pittsburgh,
Pittsburgh, PA). Reference human autoimmune sera specific for anti-
RNAP II were described previously (12, 22). Murine mAb 8WG16,
specific for the carboxyl-terminal domain (CTD) of the largest subunit
of RNAP 11 (23, 24), was a gift of Dr. Nancy E. Thompson (McArdle
Laboratory for Cancer Research, University of Wisconsin, Madi-
son, WI).
Immunoprecipitation. The proteins recognized by human autoimmune
sera were determined by immunoprecipitation of radiolabeled cell ex-
tracts and 8% SDS-PAGE as described (25). Briefly, human K562 eryth-
roleukemia cells were labeled for 14 h with 20 ACi/ml[35S]methionine
and cysteine (DuPont-NEN, Boston, MA) in methionine-free RPMI
1640 containing 10% PBS-dialyzed FBS and 3% regular RPMI. The
cells were resuspended at 107/ml in ice cold 0.5 M NaCl NET buffer
(500 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl, pH 7.5) containing
0.3% NP-40, 0.5 mM PMSF, 0.3 TIU/ml aprotinin, sonicated intermit-
tently for 120 s, and cleared by centrifugation. Protein A-Sepharose
CL4B beads (Pharmacia Fine Chemicals, Piscataway, NJ) were incu-
bated for 1 h with 10 td of human serum or 3 sl of mAb 8WG16 (1
mg/ml), and then washed twice with 0.5 M NaCl NET/NP-40 buffer.
Cell extract from 2 x 106 cells was incubated with antibody-coated
beads for 1 h at 4°C followed by washing three times with 0.5 M NaCl
NET/NP-40, and twice with NET buffer. Radiolabeled proteins binding
to the beads were analyzed by SDS-PAGE and autoradiography.
Alkaline phosphatase treatment ofRNAP II. 35S-labeled cell extract
was immunoprecipitated with 10 tl of human autoimmune sera or 3 tl
of mAb 8WG16 as above. The beads were washed three times with 0.5
M NaCl NET/NP-40, once with NET, and twice with 20 mM Tris-HCl,
150 mM NaCl, pH 8.0, 1 mM MgCl2. The beads were then resuspended
in 50 1.l of 20 mM Tris-HCl, pH 9.6, 1 mM MgCl2, containing 2 units
of calf intestine alkaline phosphatase (Boehringer Mannheim Corp.,
Indianapolis, IN), and incubated for 0.5 or 5 h at 37°C with intermittent
mixing. The same treatment without alkaline phosphatase was used as
a control. Digestion was stopped by adding 25 Al of SDS sample buffer
and the samples were analyzed by SDS-PAGE as above.
Pulse-chase analysis. K562 cells were pulse-labeled with [35S]-
methionine and cysteine as described previously (26). Briefly, 1.2 X 108
cells were washed twice with PBS, preincubated for 30 min in 2 ml of
methionine-free RPMI 1640 containing 10% PBS dialyzed FBS, and
labeled for 15 min at 37°C by adding 1.5 mCi of [35S]methionine and
cysteine. After pulse labeling, 45 ml of cold RPMI 1640 was added and
the cells were collected by centrifugation and washed with PBS. 2 x 107
pulse-labeled cells were harvested immediately, and the remaining cells
were cultured at 37°C in five tissue culture flasks (2 x 107 cells in 5
ml of complete medium per flask). One flask (2 X 107 cells) was har-
vested after 1, 2, 4, 8, and 16 h of cold chase, respectively. The cells
were washed once with PBS and frozen. The cells were then thawed
and sonicated at 2 x 107/ml in 0.5 M NaCl NET/NP-40, and the extract
was cleared by centrifugation and immunoprecipitated with 3 /1 mAb
8WG16, or 10 p1 of anti-RNAP II positive autoimmune sera as above.
Beads were washed three times with 0.5 M NaCl NET/NP-40 buffer
and once with NET buffer.
Clinical analysis. The prevalence of autoantibodies to RNA poly-
merase II and I/III was determined by immunoprecipitation for unse-
lected rheumatic disease patients seen at Keio University Hospital, Na-
tional Murayama Hospital, or Fussa Hospital, or at the University of
North Carolina Hospitals. All patients were classified as described above
using clinical criteria for SLE, MCTD/overlap syndrome, PM/DM, SSc,
Sjdgren's syndrome, or RA. Sera from healthy control subjects, patients
with pulmonary tuberculosis, or patients with cervical carcinoma were
also examined. The association of anti-RNAP II with autoantibodies to
nRNP, Sm, Ro/SS-A, La/SS-B, Ku (p7O/p8O), Ki, Jo-l, and topoisomer-
ase I (Scl-70) by double immunodiffusion and/or immunoprecipitation
were also studied.
Results
Immunoprecipitation with human autoimmune sera. Eukaryotic
RNAP II is a multisubunit complex consisting of 10-14 poly-
peptides ranging in size from 10-220 kD (27). The precise
subunit composition of the enzyme remains somewhat contro-
versial, and the structure and function of the individual subunits
of human RNAP II are still poorly characterized (28, 29). Auto-
antibodies to RNAP II have been defined previously based on
their ability to immunoprecipitate the two largest subunits of
220 kD and 145 kD, respectively, as well as the 240-kD phos-
phorylated form of the largest subunit (12, 14). Inmunoprecipi-
tation of the strongly radiolabeled 220-240- and 145-kD sub-
units is characteristic of murine mAbs as well as autoimmune
sera specific for RNAP II. The smaller subunits of RNAP II
are labeled inefficiently, and are not consistently visualized in
immunoprecipitation.
We screened human autoimmune sera for anti-RNAP II auto-
antibodies by immunoprecipitation, comparing with the mobil-
ity by SDS-PAGE of the characteristic 220-240- and 145-kD
polypeptides immunoprecipitated by the murine anti-RNAP II
mAb 8WG16 (Fig. 1, lane 3). Immunoprecipitation of RNAP
I/III components was confirmed using human reference sera
previously described by Hirakata et al. (12) (lane 1) and Okano
et al. (15), as well as anti-RNAP I, II, and III reference serum
(12, 22) (lane 2). Fig. 1 shows the immunoprecipitation patterns
of representative sera containing autoantibodies to RNAP II
from eight patients with SLE (lanes 4-11) and two patients
with SLE-overlap syndrome (lanes 12 and 13). All 10 sera
immunoprecipitated 220-240- and 145-kD polypeptides comi-
grating exactly with the largest and second largest subunits of
RNAP II that were immunoprecipitated by mAb 8WG16 (lane
3). Like 8WG16, many sera immunoprecipitated a diffuse band
or bands in the 220-240-kD range (Fig. 1, lanes 4-8). This
pattern has been shown previously to reflect phosphorylation
of the CTD of the 220-kD subunit RNAP II, resulting in a
mobility shift to 220-240 kD. The nonphosphorylated and
phosphorylated forms of RNAP II have been designated HA
and IIO, respectively, and the nonphosphorylated and phosphor-
ylated forms of the largest subunit have been termed Ha and
IHo, respectively (12, 30, 31). Some sera immunoprecipitated
the 240-kD (I1o), but not the 220-kD (Ha) form along with
the 145-kD (TIc) polypeptide (Fig. 1, lanes 9-13). With one
exception (lane 4), all anti-RNAP IT positive sera from patients
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 Figure 1. Immunoprecipitation of
RNAP II with human autoimmune
240 kD _ w _ _ _ w _ kD sera. Radiolabeled K562 cell extract
220 kD _IIAm,. -205 was immunoprecipitated with human
anti-RNAP 11111 reference serum (lane
145kD-, __ - - 1), anti-RNAP 1,1, III reference se-
rum (lane 2), mAb 8WG16 specific|a-
.
Ad -116 for RNAP H (lane 3), anti-RNAP II
W_,- _ 97 sera from patients with SLE (lanes 4-
p80 - - 11), or SLE overlap syndrome (lanes
12 and 13), or normal human serum
p70 ___ - 66 (lane 14). All sera from patients with
W
..es~bbv*AMPSLE or SLE overlap syndrome immu-
60 kD Ro -_ _ noprecipitated the 145-kD second
largest RNAP H subunit plus eithernr.. . ; ~~~~~~~~~~~~~~~~~~~4 5'uiui w- A. -~" ephosphorylated plus unphosphory-
_."W OM.&AdAMW 'Ouraw ABOW lated (240 and 220 kDa, lanes 4-8),
or only the phosphorylated (240 kD),
form of the large subunit (lanes 9-
13). One serum from a patient with
UI -A-__ SLE also immunoprecipitated RNAP
I/III (lane 4). Note the coexistence of
- anti-Ku (p70 and p80, lanes 4, 9, 10,
and 12), anti-topoisomerase I (lane
13), anti-Ro/SS-A (lanes 6, 8, and 9), and anti-Sm/RNP (Ul-A; lanes 4, 5, 8, 11-13) in some sera. Molecular weight standards in kD are shown
on the right. I, two largest subunits of RNA polymerase I; III, two largest subunits of RNA polymerase HI.
with SLE and SLE-overlap syndrome failed to immunoprecipi-
tate RNAP 11111 components, as indicated by comparison with
human anti-RNAP M/Ill reference serum (lane 1). The only ex-
ception was one serum from a patient with SLE (lane 4) that
immunoprecipitated the two largest subunits of RNAP I (197
and 126 kD) strongly as well as the two largest subunits of
RNAP II. The two largest subunits of RNAP Im (155 and 138
kD) were also seen weakly. Normal human serum did not immu-
noprecipitate components of either RNAP II or RNAP I111
(lane 14).
Alkaline phosphatase treatment ofRNAP II. To confirm that
the diffuse band migrating at 220-240 kD and the 240-kD band
immunoprecipitated by some sera, represented the large subunit
of RNAP H and its phosphorylated forms, immunoprecipitates
were treated with alkaline phosphatase (32). The mobility of
the 220-240-kD band was unaffected even after 5 h incubation
at 370C if alkaline phosphatase was not added (Fig. 2 A). As
shown in Fig. 2 B, there was no clear difference in this pattern
after 30 min of alkaline phosphatase digestion, although the
intensity of the 240-kD band in lanes 4-6 may have been some-
what weaker. However, the mobility was reduced significantly
after 5 h of alkaline phosphatase treatment (Fig. 2 C). In lane
1, although the 240-kD band immunoprecipitated by anti-RNAP
I, H, III serum remained visible, the diffuse 220-240-kD band
shifted to 220 kD. The diffuse 220-240 kD band immunopre-
cipitated by mAb 8WG16 (lane 2) as well as by human autoim-
mune sera (lanes 3 and 4) was also shifted to - 220 kD, as
shown previously using biochemically purified RNAP 11 (32).
The 240-kD band in lanes 5 and 6 shifted to 220-230 kD
after dephosphorylation. These results are consistent with nearly
complete (lanes 2 and 4) or partial (lanes 3, 5, and 6) dephos-
phorylation of the affinity-purified 240-kD band, and provide
additional evidence that the diffuse 220-240-kD band immuno-
precipitated by the patient's sera consists of the unphosphory-
lated plus phosphorylated forms of the largest subunit of RNAP
11 (30). In addition, the data suggest that some sera preferentially
A B
1 2 3 4 5 6 1 2 3 4 5 6
240 kD -_ L j a "L:220 kD --NO__M
145 kD -4 -- -a-- --- -




1 2 3 4 5 6
kD




wA...~ ~ ~ ..W
4m w - 66
Figure 2. Alkaline phosphatase
treatment of RNAP H. Radiola-
beled K562 cell extract was im-
munoprecipitated with anti-RNAP
I, II, HI reference sera (lane 1),
mAb 8WG16 (lane 2), or human
autoimnune sera that immunopre-
cipitate either the diffuse 220-
240-kD band (lanes 3 and 4) or
the 240-kD form of the large
RNAP II subunit (lanes 5 and 6).
The beads were incubated in
buffer at 37°C for 5 h without al-
kaline phosphatase (A), with alka-
line phosphatase for 30 min (B), or with alkaline phosphatase for 5 h (C). The mobility of the 220-240-kD band was unaffected if alkaline
phosphatase was not added (A). Differences were minimal after 30 min of alkaline phosphatase digestion, but significant mobility differences were
apparent after 5 h of alkaline phosphatase treatment (C). The mobilities of the 145-kD RNAP H subunit and the 70- and 80-kD Ku proteins were
unaffected by alkaline phosphatase treatment, even after 5 h. Molecular weight standards are indicated on the right.
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immunoprecipitate the phosphorylated (110) form of RNAP II. 15
The slight differences in the extent of the mobility shift seen the
after purification of RNAP II by different autoimmune sera may isti
be related to differences in the specificity of the autoantibodies. Mc
Since alkaline phosphatase treatment was performed on the tio.
beads, certain sera might contain autoantibodies that limit the 14
accessibility of the enzyme to one or more of the phosphorylated A,
sites of the RNAP II large subunit. lcE
Pulse chase analysis. RNAP II has been shown previously Vic
to be a multiprotein complex consisting of at least 10 subunits II
ranging in size from 10 to 220 kD (27, 30, 33). Although the (2',
experiments presented in Figs. 1 and 2 strongly suggested that ize
certain sera from patients with SLE or overlap syndrome immu- lIi
noprecipitate RNAP II, the specificity of the autoantibodies pa
could not be determined because sera with antibodies to any of ne
the subunits of RNAP II would be expected to coimmunopreci- me
pitate the other subunits. Pulse-chase experiments were per- au'
formed to address the question of autoantibody specificity (Fig. im
3). As expected, mAb 8WG16, which is specific for the largest as
RNAP U subunit, immunoprecipitated mainly that subunit after Rpl
Figure 3. Pulse-chase analysis. K562 cells were
pulse labeled with [35S]methionine and cysteine for
15 min at 370C followed by 1, 2, 4, 8, and 16 h of
cold chase, respectively. Cell extracts were immuno-
precipitated with mAb 8WG16 (A), anti-RNAP I, II,
HI-positive serum (B), or anti-RNAP II-positive
autoimmune sera (C and D). Note that mAb 8WG16,
kD which is specific for the 220-kD RNAP II subunit,
-2 05 and certain autoimmune sera (B and C) immunopre-
cipitated mainly that subunit after 15 min of pulse
labeling (A), but with increasing cold chase, the mo-
-116 bility of the 220-kD subunit was altered to the char-
- 97 acteristic 220-240-kD pattern (arrows) and progres-
sively more of the 145-kD polypeptide was immuno-
66 precipitated (A, arrow). Other sera
immunoprecipitated the 145-kD subunit after pulse
labeling, with immunoprecipitation of the 240-kD
band after cold chase (D). Positions of the two
45 largest subunits of RNAP I (Ia and Ib, 197 and 126
kD, respectively) and III (Ila and Hlb, 155 and 138
kD respectively) are indicated (B). Molecular weight
standards are shown on the right. Immunoprecipita-
tion of extracts from cells labeled for 14 h using
anti-RNAP I, II, III human serum (I-Ill) or 8WG16
Jm (II) are shown on the left of each panel.
min of pulse labeling (Fig. 3 A). With increasing cold chase,
e mobility of the 220-kD subunit was altered to the character-
tic 220-240-kD pattern, consistent with posttranslational
edification (phosphorylation) of that subunit (30, 31). In addi-
)n, 8WG16 immunoprecipitated progressively more of the
15-kD polypeptide with increasing time of cold chase (Fig. 3
arrow), consistent with assembly of the 220-240- and 145-
) subunits into a particle. Indeed, it has been suggested pre-
ously that the largest and second largest subunits of RNAP
interact directly with one another, probably at multiple sites
7). Immunoprecipitation of the remaining subunits was visual-
ed less clearly, consistent with previous observations (12).
imunoprecipitation using many of the anti-RNAP II sera from
tients with SLE or overlap syndrome displayed a pattern
arly identical to that of mAb 8WG16 in pulse-chase experi-
ents (Fig. 3, B and C). In the case of a serum containing
toantibodies to RNAP I and III, as well as II (Fig. 3 B),
ununoprecipitation of the components of RNAP II displayed
pattern similar to that of 8WG16, whereas the components of
NAP I also displayed a pattern compatible with autoantibody
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Table 1. Prevalence ofAutoantibodies to RNA Polymerases by Immunoprecipitation in Japanese, Caucasian, and Black Patients
with Systemic Rheumatic Diseases
Japanese Caucasian Black
Diagnosis n RNAPII I/111 n RNAPII 1/111 n RNAPII 11111
SLE 76 9% 0 29 7% 0 33 18% 3%
MCTD/Overlap 42 14% 0 1 0 0 3 67% 0
PM/DM 26 0 0 2 0 0 ND
Scleroderma 35 20% 3% 9 11% 22% 3 33% 33%
Sjogren's 13 0 0 ND ND
RA 35 0 0 6 0 0 4 0 0
Control 32 0 0 16 0 0 6 0 0
Control; Japanese: 7 healthy, 25 patients with pulmonary tuberculosis; Caucasian: 9 healthy, 7 patients with cervical carcinoma; Black: 6 patients
with cervical carcinoma. ND, not determined.
recognition of the largest subunit, i.e., immunoprecipitation of
mainly the large (197 kD) subunit after pulse labeling, followed
by coimmunoprecipitation of progressively more of the 126-kD
(second largest) subunit during cold chase (Fig. 3 B; Ta and Ib,
respectively). In contrast, the two largest subunits of RNAP HI
were immunoprecipitated with comparable intensity throughout
the pulse-chase experiment (Fig. 3 B; Imia and ilb, respectively),
consistent with the presence of autoantibodies that recognize both
RNAP III subunits or else the rapid assembly of these subunits
into a particle. Sera that immunoprecipitated primarily the 240-
kD form of the large RNAP H subunit displayed a very different
pattern (Fig. 3 D). These sera immunoprecipitated exclusively the
145-kD subunit after pulse labeling and after short periods of cold
chase, but immunoprecipitated the 145-kD polypeptide as well as
the 240-kD, but not the 220-kD, form of the large subunit after
2-16 h of cold chase. The time course of immunoprecipitation
of the 240-kD band closely paralleled that of posttranslational
modification of the 220-kD polypeptide.
Prevalence of autoantibodies to RNAP II in systemic rheu-
matic disease. Screening of randomly selected Japanese (n
= 227), Caucasian (n = 47), and Black (n = 43) rheumatic
disease patients revealed that anti-RNAP H autoantibodies were
not restricted to SSc, but were also detected at relatively high
frequency in SLE and MCTD/overlap syndrome (Table I). Sera
from 7 of 76 Japanese (9%), 2 of 29 Caucasian (7%), and 6 of
33 Black (18%) SLE patients without overlapping features of
SSc immunoprecipitated RNAP H. In overlap syndromes, anti-
RNAP TI antibodies were detected in 6 of 42 Japanese patients
(14%), and in 2 of 3 Black patients (67%) in this category.
Autoantibodies to RNAP H were frequent in SSc (7 of 35 Japa-
nese (20%) and 2 of 12 Caucasian and Black Americans (17%)
with this diagnosis). In contrast, anti-RNAP H antibodies were
not detected in PM/DM, Sjogren's syndrome or RA, or controls
without systemic rheumatic disease, including patients with pul-
monary tuberculosis and cervical carcinoma, and healthy indi-
viduals. In contrast to the association of anti-RNAP H antibodies
with several clinical subsets, anti-RNAP I/HII were highly spe-
cific for SSc. Autoantibodies to RNAP I/III were present in
only one serum from a Black SLE patient out of a total of 138
SLE patients examined (Fig. 1, lane 4, and Table I). Autoanti-
bodies to RNAP I/Ill were detected almost exclusively in pa-
tients with SSc in all racial groups.
Clinical features of anti-RNAP Il-positive SLE patients.
The relatively high prevalence of autoantibodies to RNAP H in
sera from patients with SLE or overlap syndromes contrasts
sharply with previous observations (12). For that reason, the clini-
cal presentations of patients with SLE or SLE overlap syndrome
were examined closely for features of SLE and SSc. All 19 patients
met four or more ACR criteria for the classification of SLE. De-
tailed clinical information was available for 17 patients (Table II).
In addition to manifestations of relatively low diagnostic specificity
such as arthritis and antinuclear antibodies, most patients had char-
acteristic clinical symptoms and immunological abnormalities of
SLE such as malar rash, nephritis, serositis, anti-DNA antibodies,
and anti-Sm antibodies. Features of SSc were common in the four
patients with SLE overlap syndrome (patients 6-8 and 17), but
were unusual in patients carrying the diagnosis of SLE without
overlapping features of SSc and/or PMIDM (patients 1-5 and 9-
16). Of the latter group, 5 of 13 patients had Raynaud's phenome-
non, and one had pulmonary fibrosis. None of these patients had
proximal scleroderma, sclerodactyly, or digital pitting scars. Auto-
antibodies to Sm were detected in 5 of the 17 sera, and anti-
dsDNA antibodies were present in 14 of 17. Autoantibodies to
topoisomerase I (Scl-70) were detected in one patient with SLE-
SSc overlap syndrome and one patient with SLE (Table HI, cases
6 and 10, respectively).
Among these patients, 9 of 17 with anti-RNAP II had Ray-
naud's phenomenon; however, 7 of the 9 also had anti-nRNP
antibodies, which have been reported previously to be associ-
ated with Raynaud's phenomenon (10, 34). Among the eight
anti-RNAP II-positive patients whose sera did not contain anti-
nRNP antibodies, only two had Raynaud's phenomenon, sug-
gesting that anti-nRNP rather than anti-RNAP H antibodies may
be associated with Raynaud's phenomenon in these patients.
Thus, the clinical manifestations exhibited by these patients
suggested that autoantibodies to RNAP H in SLE patients were
not limited to those patients with overlapping features of SSc.
These observations further support the idea that anti-RNAP II
antibodies are not specific for SSc.
Immunoprecipitation of the phosphorylated and unphos-
phorylated forms of the largest subunit ofRNAP II. 12 out of
32 anti-RNAP H-positive sera immunoprecipitated the diffuse
220-240-kD band consisting of the phosphorylated (IHo) and
unphosphorylated (IHa) forms of the largest subunit (group 1,
Table HI). The remaining 20 patients' sera immunoprecipitated
only the Ho form (group 2, Table III). All six sera from Japanese
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Table II. Clinical Features of Patients with SLE and SLE Overlap Syndrome with Anti-RNA Polymerase II
Case 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Age 24 27 31 32 46 33 34 45 38 40 22 38 38 43 47 66 45
Race J J J J J J J J W W B B B B B B B
SLE
1. Malar rash + + - - - + + - - - - + - + + - -
2. Discoid - - + - - - - - - - - - + + + - -
3. Photosensitivity + - - - - + - + - + + - -
4. Oral ulcers - - - - + - + - +
5. Arthritis - + + + + + + + + + + + + + + + +
6. Serositis - + + + - + - + + + -
7. Renal disorder - + + + + - + - + + + + - - - - +
8. Neurologic - - - - - +
9. Hematologic + + + - + + + + + + + + + + + - +
10. Immunologic LD DS LD LB D L LD LD D D D DS D D D D S
B B S S
11. ANA + + + + + + + + + + + + + + + + +
PM/DM - - - - - - + + - - - - - - - - +
Scleroderma
Proximal - - - - - +
Sclerodactyly - - - - - + + +
Pitting scars - - - - - +
Pulmonary fibrosis - - - - - - + - - - - - - - - + +
Raynaud's - + + - + + + + + - - - - - + - +
Autoantibodies
RNA polymerase II 1 2 1 2 2 2 2 2 1 2 1 2 2 2 1 2 1
nRNP - + - - + + + + - - + + - - + - +
Sm - + - - - - + + - - - + - - - - +
Ro + - - + + - + - - - + + + - - + +
La + + +
Ku -+ + + + + +
Su - - - - - - - - - + - + + - - - +
Others Tp *1 *2
Cases 1-5, 9-16: SLE; Cases 6-8, 17: SLE-overlap syndrome. Cases 1-16: female; Case 17: male. Race: J, Japanese; W, White (Caucasian); B,
Black (African-American). Immunologic abnormalities: L, LE cell; D, anti-dsDNA antibodies; B, biological false positive result for serological test
for syphilis. S. anti-Sm antibodies; ANA, antinuclear antibodies. Autoantibodies: For RNA polymerase H, 1 denotes group 1, unphosphorylated
(Ha) and phosphorylated (Ho) form, while 2 denotes group 2, phosphorylated (Ho) form only. Tp, anti-topoisomerase I antibodies; *1, Antibodies
to ribosomal P and topoisomerase I; *2, Antibodies to RNA polymerase I and III.
SSc patients that contained anti-RNAP II without anti-RNAP
I/III immunoprecipitated the phosphorylated form of RNAP H
only. In contrast, all three sera from SSc patients in group 1
also contained anti-RNAP I/IUH.
Table IlL Prevalence of Phosphorylated and Unphosphorylated
Form of the Largest Subunit ofRNA Polymerase II
Immunoprecipitated by Autoimmune Sera
Japanese Caucasian Black
Group I Group 2 Group 1 Group 2 Group 1 Group 2
SLE 3 4 1 1 2 4
Overlap 2 4 0 0 1 2
Scleroderma 1 6 1 0 1 0
Group 1: phosphorylated (Ho) and unphosphorylated (Ha) form; Group
2: phosphorylated (Ho) form only. None of the autoimmune sera immu-
noprecipitated only unphosphorylated form.
Association of anti-RNAP II with other autoantibodies.
Among the 19 anti-RNAP H-positive SLE patients, anti-nRNP
antibodies were found in 10 cases (Table IV). Anti-Ro antibod-
ies were found in 10, and anti-Sm and anti-Su in 6 cases each.
However, these antibodies are relatively common in SLE pa-
tients, and they were not detected significantly more frequently
in the anti-RNAP H-positive patients than in anti-RNAP II
negative individuals (data not shown). Autoantibodies to Ku
were noted in 2 out of 10 Japanese patients and 4 out of 9
American patients with SLE and anti-RNAP H antibodies. Anti-
topo I antibodies were found in 2 of 19 patients with SLE or
SLE-overlap syndrome. These results argue against the idea
that autoantibodies to RNAP II and topoisomerase I or other
SSc subset marker autoantibodies are usually mutually exclu-
sive (14, 35).
Discussion
Previous studies have suggested that autoantibodies to RNA
polymerases, including RNAP II, serve as diagnostic markers
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Table IV. Prevalence of Other Autoantibodies in Patients
with Anti-RNA Polymerase II Antibodies







Ribosomal P 2/15 0/4
Topoisomerase I 1/15 1/4
SLE: 7 Japanese, 2 Caucasian, and 6 Black patients. SLE-OL, SLE
overlap syndrome: 1 Black and 3 Japanese patients.
for scleroderma (11-15). Although the present studies are in
agreement with previous reports regarding the diagnostic speci-
ficity of autoantibodies to RNAP I/Ill, anti-RNAP II antibodies
appear to be less specific for scleroderma than they were be-
lieved to be previously. The identification of human autoanti-
bodies to RNAP II in the present study was based on immuno-
precipitation of characteristic polypeptides of 220-240 and 145
kD comigrating with proteins immunoprecipitated by mAb
8WG16 and human reference sera, pulse-chase analysis, and
the decreased mobility of the Ho (phosphorylated) form of the
large subunit immunoprecipitated by the human autoimmune
sera and the reference murine mAb after alkaline phosphatase
treatment. In addition, both the 220- and the 240-kD proteins
immunoprecipitated by SLE sera could be absorbed by preincu-
bating the extract with anti-RNAP II reference sera (data not
shown). Based on all of these criteria, the 220-240 and 145-
kD polypeptides immunoprecipitated by the human autoim-
mune sera in the present study were considered to be subunits
of RNAP II. Although we could not completely exclude the
possibility that some of the sera immunoprecipitating RNAP II
contained autoantibodies to other proteins bound to RNAP II
(32, 36), no other common proteins were seen on immunopre-
cipitation. In addition, it is possible that autoantibodies to RNAP
II in some SLE sera actually are directed against another antigen
that carries antigenic determinants crossreactive with RNAP II.
Regarding this point, three out of four sera originally selected
for the reactivity with the G8 antigen, a novel autoantigen hav-
ing sequence similarity to the CTD of RNAP 11 (37), immuno-
precipitated RNAP II (M. Satoh and W. H. Reeves, unpublished
observations [these patients are not included in the present
study]). The finding that SLE sera display two different RNAP
H recognition patterns may argue against crossreactivity of
RNAP H with another antigen, although further studies are nec-
essary.
Autoantibodies specific for the phosphorylated form of the
RNAP II largest subunit. All of the patients' sera with anti-
RNAP II described previously immunoprecipitated both the
phosphorylated (Ho) and unphosphorylated (Ha) forms of the
large subunit. In the present study, more than half of the human
anti-RNAP H autoimmune sera preferentially immunoprecipi-
tated the phosphorylated (Ho) form of the largest subunit with-
out the Ila form (Fig. 1). Identity of this band with the phosphor-
ylated form of the large subunit was confirmed by its shift
in mobility and reduced intensity after alkaline phosphatase
uAtoinirnue cpilopc Figure 4. Interpretation
of pulse chase experi-
ments. Three possible ex-
planations were found
for the immunoprecipita-
tion by some sera of only
the 145-kD (lIc) subunit
after pulse labeling, with
immunoprecipitation of
the Hc and 240-kD (Ho)
subunits, but not the 220-
kD (Ila) subunit, after
(. _cold chase (see Fig. 3 D).
(A) Autoantibody recog-
nition of an epitope of the
UIc (145 kD) subunit that
is exposed when bound
to the Io (240 kD) sub-
unit, but covered when bound to the Ila (220 kD) subunit. (B) Autoanti-
body recognition of an epitope specific to the (labeled or unlabeled) Io
subunit. (C) Autoantibody recognition of an epitope composed of both
the (labeled or unlabeled) Io and Ilc subunits.
digestion (Fig. 2) and the fact that the 240-kD band could be
absorbed completely with reference autoimmune sera specific
for RNAP II (data not shown). Finally, in pulse-chase experi-
ments, these sera immunoprecipitated the 145-kD subunit after
pulse labeling, followed by immunoprecipitation of both the
145 and the phosphorylated (Ho) form of the large subunit 2-
4 h later. It is unlikely that this pattern simply reflects recogni-
tion of the 145-kD subunit, because the HO and hA forms of
RNAP II both carry the 145-kD subunit (33), and the sera do
not immunoprecipitate the HA form. Interpretation of the pulse-
chase experiments must take into account the fact that the immu-
noprecipitation patterns reflect the kinetics of phosphorylation
and subunit assembly, as well as the epitope(s) recognized by
autoantibodies. Phosphorylation of the Ha subunit and particle
assembly occur at 2-4 h after de novo synthesis of RNAP
H subunits (Fig. 3). Taking these kinetic factors into account,
there are at least three models that might explain why some
sera specific for RNAP HO immunoprecipitated only the 145-
kD (lIc) subunit after pulse labeling (Fig. 4). One possible
explanation is that the sera may recognize an epitope of the
145-kD subunit that is covered when the Ila subunit binds, but
is exposed by time-dependent, phosphorylation-induced, con-
formational changes (38) (Fig. 4 A). Alternatively, some sera
may contain antibodies specific for the phosphorylated (ho)
form of the large subunit, and the newly synthesized (labeled)
145-kD subunit may form complexes rapidly with preexisting
(unlabeled) Ho subunits (Fig. 4 B). In this scenario, the newly
synthesized Ha subunit would not be recognized until it is phos-
phorylated 2-4 h later, thus explaining the immunoprecipitation
of the labeled 145-kD subunit, but not the large subunit, after
pulse labeling. Finally, it is possible that these sera contain
antibodies to a conformation unique to the complex of the Ho
and the 145-kD subunits (Fig. 4 C). Direct binding of these two
subunits has been reported (27), and it has been suggested that
phosphorylation of the Iha subunit causes a major change in the
conformation of RNAP 11 (38). This conformation might be
recognized by autoantibodies immunoprecipitating only the 11O
form of RNAP HI. Autoantibodies specific for conformational
epitopes formed by multiprotein or protein-nucleic acid com-
plexes have been described previously, e.g., in the case of anti-
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nucleosome antibodies and autoantibodies specific for the hu-
man Y5 Ro ribonucleoprotein particle (39, 40). Further experi-
ments will be necessary to distinguish between these possibili-
ties. Unfortunately, Western blot analysis did not resolve the
question of subunit specificity due to the poor reactivity of these
sera with RNAP II subunits after SDS-PAGE and transfer to
nitrocellulose (M. Satoh, unpublished data). This may further
support the idea that some autoantibodies recognize a conforma-
tional epitope unique to the ITO form of RNAP II. Regardless
of the explanation, these sera appear to recognize RNAP II in
a manner distinct from that displayed by other autoimmune sera
and mAb 8WG16, which immunoprecipitate only the unphos-
phorylated form of the large subunit after pulse labeling, fol-
lowed by coimmunoprecipitation of the 145-kD subunit.
The specific recognition of the phosphorylated (HO) form
of RNAP II by over half of the sera suggests that autoimmunity
may be directed selectively against the RNAP II elongation
complex, since phosphorylation of RNAP II is thought to occur
in the preinitiation complex and is required for elongation to
take place (32, 41, 42). Autoantibodies specific for the phos-
phorylated form of the large subunit may be of some interest
in view of previous suggestions that autoantibodies target active
or functional sites preferentially (43, 44), and the evidence that
phosphorylation of the large subunit is characteristic of the
transcriptionally active form of RNAP II (38, 41, 42, 45). It
has been shown previously that human autoantibodies that im-
munoprecipitate RNAP II can inhibit the catalytic activity of
the enzyme (12). However, it remains to be determined whether
autoantibodies specific for the phosphorylated form of the en-
zyme can likewise inhibit function.
Diagnostic specificity ofanti-RNAP antibodies. In the pres-
ent study, anti-RNAP II antibodies were detected in 9% of
Japanese, 7% of Caucasian, and 18% of Black SLE patients
who did not show manifestations of other rheumatic diseases.
Autoantibodies to RNAP II in SLE and MCTD/overlap syn-
dromes were rarely associated with anti-RNAP I/III antibodies,
consistent with previous observations that the latter are specific
for SSc (11-15). The single SLE patient with anti-RNAP I/
III antibodies is the first such patient reported, suggesting that
autoantibodies to RNAP I/III are extremely unusual in SLE. In
addition, in contrast to previous reports, autoantibodies to
RNAP II without anti-RNAP I/III antibodies were also detected
frequently in SSc.
Kuwana et al. (14) reported previously that antibodies to
RNA polymerases were not found in 286 controls including
190 SLE and 10 SLE-PM overlap syndrome, although anti-
RNAP I, II, III antibodies were analyzed together, and detailed
analysis of the specificities was not performed. Hirakata et al.
(121 specifically looked at anti-RNAP II and reported that anti-
RNAP II antibodies were not detected in sera from 217 controls,
including 126 SLE and 27 MCTD patients. The discrepancy
between our data and these previous reports is probably not
explained entirely by differences in the patient populations
tested, because autoantibodies to RNAP II were found in Japa-
nese as well as American patients in the present study. It is
possible that autoantibodies to RNAP II were detected more
frequently when accompanied by anti-RNAP 1/111, and that anti-
bodies to RNAP H alone were underreported due to a lower
labeling efficiency or differences in the extraction buffers used
for immunoprecipitation. Also, anti-RNAP II autoantibodies
specific for the phosphorylated form of the largest subunit,
which were present in more than half of patients with anti-
RNAP II in the present study, might have been overlooked
previously.
Association of anti-RNAP II and other autoantibodies. In
contrast to previous suggestions that anti-RNAP antibodies sel-
dom coexist with other marker autoantibodies for SSc subsets
(14, 15, 35), we found that anti-RNAP II antibodies were often
accompanied by anti-nRNP, anti-Ku, or anti-topoisomerase I
antibodies. However, sera containing all three of these specific-
ities along with anti-RNAP II were not identified. Further stud-
ies with larger numbers of patients will be necessary to verify
the significance of the associations of anti-RNAP H with other
autoantibody specificities. If confirmed by more extensive anal-
ysis, the coexistence of anti-RNAP II antibodies with anti-Ku
and anti-topoisomerase I antibodies may be of interest from
both biological and immunological points of view. RNAP II is
an in vitro substrate for phosphorylation by the Ku-p350 DNA-
dependent protein kinase complex (46). Likewise, there is recent
evidence that topoisomerase I is a cofactor for transcription by
RNAP II and that it interacts physically with both RNAP II and
the TATA binding protein (47, 48). An association of autoanti-
bodies to RNAP II with anti-Ku or anti-topoisomerase I antibod-
ies might, therefore, be consistent with the concept of linked
sets of autoantibodies specific for physically associated compo-
nents of a macromolecular complex (49). Alternatively, anti-
RNAP II, anti-Ku, anti-topoisomerase I, and probably anti-
nRNP antibodies may all be associated with the same clinical
subset, or reactivity with multiple antigens might reflect autoan-
tibody recognition of shared epitopes. Studies with larger num-
bers of patients are necessary to confirm the true associations
of anti-RNAP II autoantibodies with other specificities and to
explain the these associations.
In summary, we report here that anti-RNAP II antibodies
are common in SLE and MCTD/overlap syndrome and are not
a disease marker for SSc, whereas anti-RNAP /III antibodies
appear highly specific for SSc. In over half of the patients,
the autoantibodies were specific for the transcriptionally active
phosphorylated form of the enzyme. Whether particular anti-
RNAP II antibodies have other clinical significance, such as an
association with specific symptoms or prognosis, may be clari-
fied in future studies. Further investigation of the immunologic
basis for the possible linkage of anti-RNAP II antibodies with
other autoantibodies may help in understanding why certain
autoantibodies serve as specific markers for clinical subsets of
rheumatic disease.
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